Sacubitril-valsartan and Heart Failure Patients : the ENTRESTO-SAS Study
Status:
Completed
Trial end date:
2020-02-27
Target enrollment:
Participant gender:
Summary
Chronic Heart Failure (CHF) is a frequent pathology burdened with mortality and significant
morbidity. Sleep apnea syndrome (SAS) is frequently associated with CHF in 20% to 75% of
cases. Treatment of SAS is however inconsistently associated with a decline in the morbidity
and mortality. To date, the CHF medical treatments have been reported to be inconsistently
efficient in the treatment of SAS.
SACUBITRIL-VALSARTAN (ENTRESTO®) is a new treatment of CHF recently indicated class I, level
B in the recent European Society of Cardiology (ESC) guidelines 2016 on CHF. PARADIGM-HF
trial demonstrated that morbidity and mortality can be improved with SACUBITRIL-VALSARTAN. In
comparison to enalapril, it reduced the occurrence of cardiovascular death or hospitalisation
for CHF by 20% with a 16% reduction in all-cause mortality.
The purpose of the research is the evaluation of SACUBITRIL-VALSARTAN combination in CHF
patients presenting sleep apnea syndrome. A three months real life observational trial is
performed. A measure of the Apnea Hypopnea Index is realised before and after 3 months of
SACUBITRIL-VALSARTAN treatment. A concomitant evaluation of cardiological and quality of life
parameters is realized.
Phase:
Phase 4
Details
Lead Sponsor:
University Hospital, Montpellier
Treatments:
LCZ 696 Sacubitril and valsartan sodium hydrate drug combination Valsartan